Navigation Links
Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
Date:1/5/2009

SAN DIEGO, Jan. 5 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that the United States Patent and Trademark Office (USPTO) has issued a patent for what the Company refers to as the "Weber/Cowley methods patent" (U.S. Patent No. 7,462,626), which provides coverage for Contrave(R), the Company's lead obesity product candidate now in Phase 3 clinical trials.

The patent broadly covers methods of treating obesity with combinations of bupropion and naltrexone, the two active agents in Contrave. It is a companion to the Weber/Cowley composition patent (U.S. Patent No. 7,375,111) which was issued by the USPTO in May 2008 and broadly covers sustained release (SR) compositions of bupropion and naltrexone combined in a single dosage form. The Weber/Cowley methods patent will provide protection for Contrave through mid 2024.

"The issuance of this patent adds another layer of protection for Contrave, which we believe enhances its net present value," said Eckard Weber, M.D., the Company's Interim President and CEO. "Contrave is now protected by four patents that we believe will provide broad intellectual property coverage."

About Contrave(R)

Contrave is an investigational oral weight loss medication with a mechanism of action that works at two levels within the central nervous system: one that controls the balance of food intake and metabolism and another which controls food preference and cravings (also known as the reward center). In fact, we believe that Contrave may be the first treatment for obesity to target these reward centers. In clinical trials, Contrave is believed to initiate and sustain significant weight loss over one year of treatment we believe by reducing appetite, increa
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
2. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
3. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
4. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
5. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
6. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
7. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
8. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
9. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
10. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
11. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014  Organovo announced ... from the National Institutes of Health (NIH) to help ... effective treatments to patients on a faster timeline. Organovo ... Sciences (NCATS) and the National Eye Institute (NEI) to ...
(Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation ... developing and commercializing innovative therapies addressing major unmet ... it received the Notice of Allowance from the ... unique self-delivering RNAi compounds (sd-rxRNA®), for the treatment ...
(Date:1/14/2014)... UK (PRWEB) January 13, 2014 Bob ... with more than 20 years in the industry, has ... photonics . Hainsey will serve as the society’s Science ... Dr. Hainsey join SPIE as our Technology Strategist, further ...
(Date:1/14/2014)... Independent publisher Bitingduck Press, with offices ... has big ideas for 2014 in production and sales ... to produce high-quality, low-cost, DRM-free ebooks and to use ... , The first major development will be bookstore sales ...
Breaking Biology Technology:Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... Robert G. Johnson, Jr. Resigns as President and ... Near-Term Commercial Opportunities, HAYWARD, Calif., Feb. 28 ... announced that Robert G. Johnson, Jr.,M.D., Ph.D., has ... a,member of Kosan,s Board of Directors. Helen S. ...
... payment, WILMINGTON, N.C., Feb. 28 PPD, ... Limited,s new drug,application (NDA) for alogliptin, a highly ... diabetes, has been accepted for filing by the ... to develop the,compound., Under PPD,s agreement with ...
... Feb. 28 The Center for Molecular,Medicine (CMM) today ... the,nation to offer a new, FDA-approved test that will ... CMM (http://www.cmmdx.org ) is offering the CellSearch(TM) System ... new tool in managing,patients with metastatic prostate cancer (MPC). ...
Cached Biology Technology:Kosan Announces Senior Management Changes and Clinical Portfolio Priorities 2Kosan Announces Senior Management Changes and Clinical Portfolio Priorities 3Kosan Announces Senior Management Changes and Clinical Portfolio Priorities 4Kosan Announces Senior Management Changes and Clinical Portfolio Priorities 5Kosan Announces Senior Management Changes and Clinical Portfolio Priorities 6Kosan Announces Senior Management Changes and Clinical Portfolio Priorities 7Kosan Announces Senior Management Changes and Clinical Portfolio Priorities 8PPD Confirms Takeda's NDA Filing of Alogliptin with U.S. Food and Drug Administration 2Center for Molecular Medicine Among First to Offer New FDA-Approved Test to Aid in Treatment of Prostate Cancer 2
(Date:4/17/2014)... Several parasites and pathogens that devastate honeybees in Europe, ... Africa, but do not appear to be impacting native ... team of researchers., The invasive pests include including ... East African honeybees appear to be resilient to these ... used to control pests in Europe, Asia and the ...
(Date:4/17/2014)... serious conditions such as heart disease, epilepsy and pain, ... Unfortunately, there is still much scientists do not know ... unexpected insight into the structure of sodium channels and, ... which are responsible for ,fine-tuning, the activity of the ... edition of the Journal of Biological Chemistry . ...
(Date:4/17/2014)... BLOOMINGTON, Ind. -- Indiana University researchers have detected new ... with diabetes. This discovery could have far-reaching implications for ... the care of over 25 million Americans. , "We ... the retinas at such early stages," said Ann Elsner, ... Optometry and lead author of the study. "We set ...
Breaking Biology News(10 mins):East African honeybees are safe from invasive pests… for now 2East African honeybees are safe from invasive pests… for now 3Structure of sodium channels different than previously believed 2New technique detects microscopic diabetes-related eye damage 2New technique detects microscopic diabetes-related eye damage 3
... nature,s repository of chemicals in plants, microbes, and marine ... be a major theme of a five-day scientific conference ... 1,200 natural products researchers from around the world. ... the City University of New York, and other New ...
... Imagine millions of cancer cells organized in thousands of small ... die, you have a candidate for a cancer drug. But ... Opinion on Drug Discovery argues that these 2D models ... effects in the body and may often give researchers misleading ...
... Fla. (July 19, 2012) A study comparing whether endothelial ... from human umbilical cord blood are more proliferative and better ... from human placenta are more vasculogenic., The study, carried out ... in a recent issue of Cell Medicine [2(3)] ...
Cached Biology News:Nature as a source of new medicines subject of ICNPR in NYC 2Nature as a source of new medicines subject of ICNPR in NYC 33-D tumor models improve drug discovery success rate 23-D tumor models improve drug discovery success rate 3Blood vessel forming potential of stem cells from human placenta and umbilical cord blood 2
The imaging screen-K (Kodak), is a 35 x 43 cm storage phosphor screen that is used for the quantitation and imaging of 32P, 33P, 35S, 14C, and 3H....
The filter 695RDF55 Reflect 635 for the Molecular Imager FX is a band pass filter for Cy5 and Alexa Fluor 635 dyes....
... is a 2-color staining method for labeling ... detect apoptotic cells by flow cytometry. The ... for measuring apoptosis in cells, including positive ... performance; washing, reaction and rinsing buffers for ...
The sample holders for gels are used to hold gels in place in the multi-sample tray I, which is used with Molecular Imager FX imaging systems....
Biology Products: